# A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis

> **NCT05090904** · PHASE2 · COMPLETED · sponsor: **Insmed Incorporated** · enrollment: 29 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** Brensocatib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05090904
- **Lead sponsor:** Insmed Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-30
- **Primary completion:** 2022-11-01
- **Final completion:** 2022-11-01
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05090904

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05090904, "A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05090904. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*